The Ensign Group (NASDAQ: ENSG) Securities Class Action: Nursing-Home Compliance Allegations and December 7, 2026 Lead Plaintiff Deadline

The complaint alleges that Ensign publicly emphasized high-quality patient care, clinical excellence, strong CMS quality metrics, and regulatory compliance, while allegedly failing to disclose that aspects of its business depended on practices the complaint describes as understaffing, inadequate resident care, manipulation of quality-related data, Medicare and Medicaid billing misconduct, and improper administrator-licensing arrangements.

In particular, plaintiff alleges Ensign did not adequately disclose problems involving:

• nursing-home staffing;
• resident care;
• quality reporting;
• Medicare and Medicaid billing; and
• facility licensing.

The complaint relies substantially on two investigative short-seller reports published in June 2026 by Hunterbrook Media and Muddy Waters Research. This is best understood as a healthcare-compliance, nursing-home-staffing, and quality-metrics disclosure case. The allegations have not been proven, and no court has found that Ensign operated any such scheme.

The Ensign Group is a Delaware corporation whose affiliated companies operate and invest in skilled-nursing, senior-living, rehabilitation, and related healthcare businesses — including physical, occupational, and speech therapy and healthcare real estate — across hundreds of affiliated facilities in numerous states. Its shares trade on Nasdaq under the ticker ENSG.

The complaint identifies CEO Barry R. Port and CFO Suzanne D. Snapper as the individual defendants. Ensign operates through a decentralized model involving numerous affiliated skilled-nursing and healthcare operations.

The proposed class period begins February 10, 2022, following Ensign's filing of its 2021 Form 10-K. That filing — and later ones — warned investors about government audits, Medicare and Medicaid compliance, False Claims Act liability, Anti-Kickback Statute enforcement, CMS inspections, and quality-of-care regulation.

Importantly, plaintiff does not allege that Ensign failed to mention healthcare regulatory risk at all. Instead, plaintiff alleges those disclosures misleadingly presented serious compliance failures as contingent, future risks when — according to the complaint — the underlying misconduct was already occurring. That distinction is central to the case.

Shortly before the June 2026 reports, Ensign announced strong Q1 2026 results on April 30, 2026. CEO Barry Port described the company's performance as reflecting a 'patient-focused culture' and emphasized high-quality clinical outcomes, CMS survey outperformance, strong Five-Star Quality Measure results, and 'sustained clinical excellence.'

The complaint alleges those statements were misleading because, according to plaintiff, Ensign's underlying staffing and quality practices contradicted the public description. Ensign has continued to point to its CMS-reported quality metrics.

CMS's Five-Star Quality Rating System helps consumers compare nursing homes. A facility's rating incorporates several types of information, including health inspections, staffing, and quality measures.

The complaint alleges that Ensign's public quality ratings did not accurately reflect actual facility conditions because certain components depended on information supplied or reported by the facilities themselves, and that staffing and quality-related data were manipulated. Those allegations have not been adjudicated.

Yes. Before the June 2026 short reports, Ensign had disclosed an ongoing DOJ Civil Investigative Demand received in 2024, concerning whether claims had been submitted to Medicare and Texas Medicaid for services that were unnecessary or otherwise inconsistent with reimbursement requirements. The CID covers conduct beginning in January 2016 and continuing to the present, and Ensign has stated that it is fully cooperating and cannot predict the outcome.

This matters for two reasons. First, the securities plaintiff's theory is not that Ensign concealed the existence of every regulatory inquiry — it is that Ensign's disclosures allegedly failed to reveal the nature and extent of the underlying misconduct now alleged. Second, the 2024 CID relates generally to healthcare-reimbursement compliance, but it does not necessarily duplicate Hunterbrook's staffing allegations or Muddy Waters' administrator-license theory, and it should not be treated as a government endorsement of the short sellers' separate claims. The existence of a Civil Investigative Demand does not establish liability.

Yes. In 2013, Ensign agreed to pay $48 million to resolve federal allegations that six Southern California skilled-nursing facilities submitted inflated Medicare claims for unnecessary therapy or services allegedly not provided. Ensign did not admit liability and entered into a Corporate Integrity Agreement.

Ensign also disclosed a separate 2018 DOJ Civil Investigative Demand regarding relationships between certain skilled-nursing facilities and medical directors or other referral sources under the False Claims Act and Anti-Kickback Statute; Ensign later disclosed that the DOJ declined to intervene in 2020. This history provides context, but it is separate from the current securities lawsuit and does not establish the truth of the 2026 allegations.

On June 8, 2026, Hunterbrook Media published an investigation titled 'Ensign: The Nursing Home Empire Built on Fatal Neglect,' which it described as the result of a five-month investigation. Hunterbrook alleged that Ensign reduced skilled-nursing staffing after acquisitions, generated profits through reduced care, relied on self-reported data that could inflate quality metrics, understaffed facilities, exposed residents to inadequate care, and engaged in improper billing or documentation practices. The report relied on CMS data, employee and resident interviews, litigation and facility records, and statistical analyses, and alleged that some residents suffered serious harm.

One of Hunterbrook's central quantitative claims was that, after analyzing CMS records covering roughly 161 Ensign acquisitions and comparing them with thousands of other facilities, total nursing hours and registered-nurse hours declined and the staffing mix shifted toward less highly trained staff, yet ratings often improved. Hunterbrook separately published its methodology.

These are Hunterbrook's allegations — not regulatory findings or adjudicated facts. Hunterbrook also disclosed that its investment affiliate, Hunterbrook Capital, held a short position in ENSG at publication and could therefore benefit financially from a decline in the stock.

According to the complaint, ENSG fell $13.88 per share — approximately 8.15% — to close at $156.42 on June 8.

On June 11, 2026, Muddy Waters Research published a separate short report, expressly disclosing that 'Muddy Waters is Short Ensign.' The report focused principally on an alleged Nursing Home Administrator 'license-rental' scheme — claiming that certain facilities identified licensed administrators of record while other individuals actually performed day-to-day management. Muddy Waters said its investigation included former-employee interviews, CMS reports, alleged administrator agreements, and site visits, and estimated that approximately 20% of facilities could be implicated, based on its own methodology.

Skilled-nursing facilities generally operate under state licensing regimes requiring an appropriately licensed administrator. The Muddy Waters theory alleges that some Ensign facilities nominally maintained a licensed Administrator of record while other persons actually ran operations — an arrangement it characterized as 'license rental.' Ensign has not been found liable for the alleged scheme, and the allegation has not been proven by a court or regulatory agency.

According to the complaint, ENSG declined $4.52 per share — approximately 2.98% — to close at $147.13 on June 11.

On June 18, 2026, Hunterbrook published a follow-up report titled 'New: Patients Hungry in Ensign Facilities,' saying that employees and residents had contacted it after the initial investigation. The follow-up included allegations involving inadequate food, understaffing, payroll and staffing-hour reporting, staff licensing, insufficient RN coverage, and residents allegedly left without adequate assistance.

According to the complaint, ENSG declined $2.19 per share — approximately 1.4% — to close at $153.65 that day. Notably, ENSG had recovered from its June 11 closing price before this June 18 decline, so the three percentage drops should not be read as one continuous, cumulative fall.

Both reports require context. Hunterbrook disclosed that an affiliated investment fund was short ENSG, and Muddy Waters expressly disclosed a short position. A short position can produce a financial gain if a company's stock declines, so both publishers had an economic interest that could benefit from a drop in ENSG.

That financial interest does not establish that the reports are false. But it does mean their allegations should be described as third-party allegations rather than government findings or judicial determinations. Whether the reports revealed previously concealed facts, merely raised new allegations, or caused losses recoverable under federal securities law — a corrective-disclosure and loss-causation question — will be an important issue in the litigation.

The complaint states that, as of June 23, 2026, Ensign had not publicly issued a detailed, point-by-point response to the Hunterbrook and Muddy Waters reports. Subsequent company reporting provides important balance. In July 2026, Ensign announced strong Q2 results and emphasized CMS-reported clinical metrics, stating that none of its 398 affiliated facilities were designated CMS Special Focus Facilities, that RN retention exceeded relevant averages, that administrator turnover was substantially lower than industry peers, and that certain clinical outcomes outperformed national benchmarks. Ensign also raised its full-year earnings and revenue guidance.

Those company statements do not themselves resolve the short sellers' allegations — just as the short-seller allegations do not themselves establish regulatory violations. The page keeps both points in view.

CMS identifies certain nursing homes with a history of serious quality problems for heightened oversight through its Special Focus Facility (SFF) program. Ensign reported in July 2026 that none of its 398 affiliated facilities carried an SFF designation.

That fact provides relevant company-side context, but it does not independently resolve every staffing, billing, or licensing allegation in the lawsuit. The absence of an SFF designation does not establish that the reports' allegations were false, and the short-seller allegations do not establish regulatory violations.

Section 10(b) and Rule 10b-5

The complaint asserts federal securities-fraud claims under Section 10(b) and Rule 10b-5 against Ensign and the individual defendants.

Section 20(a)

The complaint asserts controlling-person claims against CEO Barry Port and CFO Suzanne Snapper.

A Three-Disclosure, Multi-Report Case

The complaint identifies three disclosure dates — June 8, June 11, and June 18, 2026 — each tied to a report from a private, investment-linked investigative organization. It is therefore a multi-disclosure case rather than a single-event stock drop, and the loss-causation analysis will be an important part of the litigation.

The alleged class period is February 10, 2022 through June 18, 2026, inclusive.

Investors should preserve all brokerage statements and transaction records showing ENSG purchases and sales during the class period.

The current published PSLRA lead plaintiff deadline is December 7, 2026, as identified in the PSLRA notice published by the Rosen Law Firm.

Do I Have to Become Lead Plaintiff?

Generally, no. The lead plaintiff is the court-appointed investor who actively represents the proposed class and supervises proposed lead counsel. Most investors do not serve as lead plaintiff and remain passive class members.

Lead Plaintiff Deadline ≠ Settlement Claim Deadline

These are different dates. An investor's potential right to participate in a later certified class or settlement ordinarily does not depend on seeking appointment as lead plaintiff.

Generally, no. Securities-class eligibility turns on matters such as qualifying purchases, sales, recognized losses, and the applicable damages methodology; selling the stock does not automatically eliminate a securities claim. Continued ownership is a different issue that matters for shareholder derivative standing.

Yes. On July 16, 2026, a shareholder filed Thompson v. Keetch, et al. (Case No. 2026-01584212-CU-NP-CXC) in the Superior Court of California, County of Orange. According to Ensign's SEC filings, that action asserts claims involving healthcare regulatory compliance, staffing, executive compensation, stock sales by certain defendants, related-party transactions, breach of fiduciary duty, and unjust enrichment, with the company named as a nominal defendant.

Because a derivative action already exists, any additional shareholder investigation has to be framed around possible additional, overlapping, or distinct rights — not as a first-of-its-kind case. Those derivative claims have not been adjudicated.

Potentially. Ensign is a Delaware corporation, so potential derivative rights must be analyzed under Delaware corporate law — including contemporaneous ownership, continued ownership, demand or demand-futility requirements, adequacy, and overlap with the already-pending Thompson action. Being a long-term shareholder does not by itself create a viable derivative claim.

Julie & Holleman LLP is investigating whether current Ensign shareholders may have additional, overlapping, or distinct shareholder derivative and corporate-governance rights arising from the conduct alleged in the securities complaint and the related reports. Because the alleged conduct spans more than four years, the relevant acquisition date may depend on the particular corporate act being investigated; we are interested in speaking with current shareholders who owned ENSG at the time of potentially actionable conduct and have continued to hold their shares. Potential areas of investigation include:

• healthcare-compliance oversight — board reporting on CMS surveys, Medicare and Medicaid compliance, DOJ CIDs, facility deficiencies, and resident safety;
• staffing oversight — RN/CNA staffing data, minimum-staffing compliance, turnover, staffing after acquisitions, and internal escalation of understaffing complaints;
• quality-metric reporting — CMS staffing submissions, self-reported metrics, Five-Star ratings, and internal versus public quality measurements;
• administrator licensing — how Administrator-of-record requirements were monitored and audited, and who actually supervised facility operations;
• acquisition oversight — whether compliance and staffing systems scaled as Ensign grew through acquisitions; and
• disclosure controls — how management reconciled internal compliance data with public statements about quality, clinical excellence, and CMS performance.

The existing derivative action also raises related-party-transaction and insider-stock-sale issues. On the insider point, a preliminary review counsels caution: a February 2026 Form 4 for CFO Suzanne Snapper reports option exercises and sales made pursuant to a Rule 10b5-1 trading plan adopted September 12, 2025, and a May 18, 2026 Form 4 for CEO Barry Port reports a 550-share disposition coded as tax withholding on restricted-stock vesting rather than a discretionary market sale. Those filings do not, by themselves, establish unlawful insider trading.

Counsel may evaluate whether additional investigative steps, including available Delaware corporate-information rights, are appropriate in light of the existing derivative litigation and the narrower post-2025 scope of Delaware's books-and-records statute. Because derivative litigation already exists, any additional claim requires careful analysis of standing, overlap, demand requirements, and litigation strategy, and no determination has been made that additional viable derivative claims exist.

Julie & Holleman LLP is investigating allegations involving The Ensign Group, ENSG, skilled-nursing facilities, healthcare staffing, CMS Five-Star ratings, Medicare, Medicaid, False Claims Act compliance, the Hunterbrook and Muddy Waters reports, administrator licensing, regulatory investigations, and shareholder derivative rights. We are interested in hearing from:

Investors With Securities Losses

Investors who purchased or otherwise acquired Ensign securities between February 10, 2022 and June 18, 2026 and suffered losses, including investors evaluating whether to seek lead-plaintiff appointment before December 7, 2026.

Current ENSG Shareholders

Current shareholders who owned ENSG during potentially actionable conduct and continue to hold their shares and wish to evaluate whether additional corporate-governance or derivative rights may exist.

A shareholder may potentially fall within both groups.